• ABVC BioPharma filed a Form 12b-25 late notice for its quarterly report for period ended March 31, 2026.
• Form 10-Q missed deadline as management was unable to finalize report and XBRL exhibit without unreasonable effort or expense.
• Filing targeted within SEC extension window of five calendar days following prescribed due date.
• Notice indicated no expected significant change in results of operations versus corresponding prior-year period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABVC Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-057917), on May 15, 2026, and is solely responsible for the information contained therein.